Stenosis News and Research

RSS

A stenosis is an abnormal narrowing in a blood vessel or other tubular organ or structure.

InfraReDx's LipiScan IVUS Coronary Imaging System to be featured at EuroPCR 2010

InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased coronary tissue and guide therapeutic interventions, today announced that its next-generation LipiScan IVUS Coronary Imaging System will be featured at EuroPCR 2010, an international educational conference focused on introducing the latest techniques, updates and breakthrough science to the interventional cardiology community.

27 May 2010

CREST study data published in The New England Journal of Medicine

Data from the CREST (Carotid Revascularization Endarterectomy vs. Stenting Trial) study were published today in The New England Journal of Medicine. In this trial, stenting and surgery had similar initial safety and longer-term outcomes for symptomatic and asymptomatic men and women. Adverse event rates of death, stroke and heart attack were also similar for both therapies.

27 May 2010

New clinical data for CoreValve transcatheter aortic valve replacement system presented at EuroPCR

New clinical data presented today at EuroPCR demonstrate positive long-term performance and durability for the CoreValve transcatheter aortic valve replacement system from Medtronic, Inc. Two-year results from the pivotal 18-French CoreValve multicenter prospective study provide important additional evidence supporting wider use of the world's market-leading transcatheter aortic valve.

26 May 2010

Applied Spine Technologies awarded U.S. patents for 'Dynamic Spine Stabilizer' and 'Spring Junction'

Applied Spine Technologies, Inc., a medical device company focused on motion preservation of the lumbar spine, was awarded two new patents by the U.S. Patent and Trademark Office on May 11, 2010.

25 May 2010

Data from MiDAS I trial of mild for treatment of LSS to be released

Medical device company Vertos Medical, Inc. has announced the release of additional patient outcomes data from the MiDAS I trial, a prospective, 75-patient study of mild for the treatment of lumbar spinal stenosis. As presented at the Florida Society of Interventional Pain Physicians Annual Meeting in Orlando on May 23, investigators found that study participants reported statistically significant improvement in both their physical and mental well-being six weeks following the mild procedure.

24 May 2010

CTT's Calmare Pain Therapy Treatment decreases pain associated with CIPN

Competitive Technologies, Inc. today announced the issuance of an abstract from a study which has shown the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy using CTT's Calmare Pain Therapy Treatment.

21 May 2010

Elevated levels of Lp-PLA2 associated with increased risk of coronary heart disease

A meta-analysis of approximately 80,000 individuals from 32 prospective studies was published in The Lancet on May 1, 2010. The data shows that elevated levels of lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular-specific inflammatory enzyme, are associated with an increased risk of coronary heart disease similar in magnitude to that with non-HDL cholesterol or systolic blood pressure.

20 May 2010

Study reveals association between depression and coronary spasm

A study published in the current issue of Psychotherapy and Psychosomatics explores the relationship between depression and coronary artery spasm.

18 May 2010

Alphatec Spine reports 25.6% increase in first-quarter 2010 revenue

11 May 2010

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Patients treated with the Zilver® PTX™ Drug-Eluting Peripheral Stent maintained clinical improvement at two years, according to interim results from the Zilver® PTX™ Global Registry presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 33rd Annual Scientific Sessions.

10 May 2010

CSI announces completion of enrollment in CALCIUM 360° clinical trial for PAD

Cardiovascular Systems, Inc. (CSI), has completed patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company's 360° Clinical Series. The CALCIUM 360° feasibility study is evaluating the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI's Diamondback 360® System, a minimally invasive catheter for treating PAD anywhere in the leg. Dr. Nicolas Shammas, an interventional cardiologist at Trinity Medical Center, Bettendorf, Iowa, is the study's principal investigator.

30 Apr 2010

USPTO issues new patent to Applied Spine Technologies

Applied Spine Technologies, Inc. www.appliedspine.com, a medical device company focused on motion preservation of the lumbar spine, has been awarded a new patent titled "Spinal Stabilization Device with Weld Cap".

29 Apr 2010

VertiFlex enrolls 100 patients in Superion Interspinous Spacer IDE clinical trial

VertiFlex, Inc., a leading innovator of minimally invasive and motion preserving spinal surgery technologies, today announced that 100 patients have been enrolled in its pivotal IDE clinical trial of the Superion Interspinous Spacer (ISS).

27 Apr 2010

Prevention and nonsurgical treatment options to prevent low back pain and protect spine

Back and neck problems can be caused by a herniated disc, spinal stenosis, injury, strain or osteoarthritis. "Although more than 75 percent of Americans will experience some back pain during their lifetime, about 90 percent of cases are resolved without surgery," stated John K. Ratliff, MD, FACS, a Philadelphia spine surgeon and American Association of Neurological Surgeons spokesperson.

24 Apr 2010

Facet Solutions announces data from ACADIA lumbar stenosis pilot study

Facet Solutions, Inc. today announced that it has finished compiling two year data from its lumbar stenosis pilot study in the US. At two years, patients in the ACADIA™ study experienced significant and sustained improvement in Oswestry Disability Index, VAS back pain and VAS leg pain. There were no re-operations in any of the patients, and all patients met the definition of success for ODI improvement.

23 Apr 2010

Interventional Spine to present at and participate as sponsor of Spine Technology Summit

Interventional Spine, Inc., a privately held medical device manufacturer focusing on diseases of the spine, will present at the Spine Technology Summit at the Roosevelt Hotel in New Orleans on Monday April 26th. This annual event is a showcase for 40 new technology companies and attracts investors, industry, practitioners and analysts.

22 Apr 2010

Surgical treatment for certain injuries helps NFL athletes return to the game faster

The Bonati Spine Institute, the leading center for the patented Bonati Spine Procedures for minimally invasive laser spine surgery, reports that recent studies indicate that surgical intervention is the best treatment option for certain back injuries.

21 Apr 2010

Magnetically guided nanoparticles for delivering DNA, cells and drugs

Scientists and engineers have used uniform magnetic fields to drive iron-bearing nanoparticles to metal stents in injured blood vessels, where the particles deliver a drug payload that successfully prevents blockages in those vessels. In this animal study, the novel technique achieved better results at a lower dose than conventional non-magnetic stent therapy.

20 Apr 2010

First US implant of Interventional Spine's RENEW Interspinous Allograft Technology for LSS

Interventional Spine, Inc. today announced the first commercial implant in the United States of its RENEW™ Interspinous Allograft Technology for the Treatment of Lumbar Spinal Stenosis (LSS).

19 Apr 2010

Alphatec Holdings prices underwritten public offering of common stock

Alphatec Holdings, Inc., the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced that is has priced an underwritten public offering of 16,000,000 shares of common stock, consisting of 8,000,000 shares to be sold by the Company and 8,000,000 shares to be sold by a selling shareholder, HealthpointCapital Partners, L.P., at a price to the public of $5.00 per share.

16 Apr 2010